2023
Evolution of predictive risk factor analysis for chemotherapy-related toxicity
Hertz D, Lustberg M, Sonis S. Evolution of predictive risk factor analysis for chemotherapy-related toxicity. Supportive Care In Cancer 2023, 31: 601. PMID: 37773300, DOI: 10.1007/s00520-023-08074-x.Peer-Reviewed Original ResearchConceptsTreatment-related toxicityBiomarker discovery approachClinical practiceTaxane-induced peripheral neuropathyChemotherapy-related toxicitySame treatment regimenMaximum treatment benefitRisk factor analysisPrecision oncology treatmentsToxicity riskPeripheral neuropathyTreatment regimenSimilar patientsToxicity predictorsTreatment benefitPharmacogenetic predictorsOncology treatmentSide effectsTherapeutic outcomesCancer treatmentMinimal toxicityIntegrated biomarkersGermline genomicsBiomarker sciencePatients
2013
A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC).
Mrozek E, Wesolowski R, Lustberg M, Layman R, Ling Y, Schaaf L, Phelps M, Ivy S, Grever M, Shapiro C. A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2013, 31: 1043-1043. DOI: 10.1200/jco.2013.31.15_suppl.1043.Peer-Reviewed Original ResearchTriple-negative breast cancerMaximum-tolerated doseNon-hematologic toxicitiesNeoadjuvant chemotherapyAUC 5G4 neutropeniaDay 1Gamma secretase inhibitor RO4929097Cycles of NACGrade 4 thrombocytopeniaComplete pathologic responseTreatment-related toxicityMinimal residual cancerMinimal residual diseaseLC-MS/MS assaysAUC 6G3 anemiaG3 fatigueG3 neutropeniaG3 thrombocytopeniaG4 thrombocytopeniaStarting dosePathologic responseResidual cancerOral inhibitor